Hologic, Inc.
HOLX
Classifica tra le azioni
#1326
Hologic, Inc. is a medical technology company focused on designing, producing,... Hologic, Inc. is a medical technology company focused on designing, producing, and marketing a diverse range of diagnostic tests, medical imaging systems, and surgical solutions. Its core mission is to enhance women's health through proactive detection and effective treatment, serving patients in the United States, across Europe, the Asia-Pacific region, and various other international markets. The company operates through four distinct business units: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. Within its Diagnostics segment, Hologic provides Aptima molecular diagnostic assays for identifying infectious microorganisms, alongside Aptima viral load tests for conditions like HIV, Hepatitis C, and Hepatitis B. It also offers Aptima and Panther Fusion SARS-CoV-2 assays for detecting the virus, the ThinPrep System for cytology applications, and the Rapid Fetal Fibronectin Test to help clinicians assess the likelihood of premature birth. Furthermore, the company supplies various diagnostic tests for Group B Streptococcus. The Breast Health division delivers advanced imaging and analytical solutions, including 2D and 3D digital mammography systems with accompanying reading workstations. This segment also features minimally invasive breast biopsy guidance systems and devices, products for marking and localizing breast biopsy sites, specimen radiology tools, ultrasound solutions, connectivity options, and products supporting breast-conserving surgical procedures. For GYN Surgical needs, Hologic offers the NovaSure Endometrial Ablation System, designed to manage abnormal uterine bleeding, and the MyoSure Hysteroscopic Tissue Removal System for the excision of uterine fibroids, polyps, and other pathologies. Additionally, the Fluent Fluid Management System facilitates liquid distention during diagnostic and operative hysteroscopic interventions. The Skeletal Health segment includes the Horizon DXA, a dual-energy X-ray system, and the Fluoroscan Insight FD mini C-arm, which is utilized for minimally invasive orthopedic surgical procedures. Hologic distributes its comprehensive product portfolio through a combination of its dedicated direct sales and service teams, as well as via independent distributors and sales representatives. Established in 1985, Hologic, Inc. maintains its corporate headquarters in Marlborough, Massachusetts.
Prezzo delle azioni
$76.01
Ultima sincronizzazione: 2026-04-07
Capitalizzazione di mercato
$16.97B
Variazione (1 giorno)
0.00%
Variazione (1 anno)
2.74%
Paese
US
Scambia Hologic, Inc. (HOLX)
Categoria
Healthcare
Ricavi di Hologic, Inc. (HOLX)
Ricavi nel Dec 2025 TTM: $4.13B
Secondo gli ultimi rapporti finanziari di Hologic, Inc., i ricavi attuali dell'azienda (TTM) sono pari a $4.13B. Nel 2024, l'azienda ha registrato ricavi di $4.03B una diminuzione rispetto a i ricavi dell'anno 2023, che erano pari a $4.03B. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Hologic, Inc. da 2000 a 2026
Ricavi alla fine di ogni anno
| Anno | Ricavi | Cambia |
|---|---|---|
| 2026 (TTM) | $4.13B | 0.63% |
| 2025 | $4.10B | 1.74% |
| 2024 | $4.03B | 0.00% |
| 2023 | $4.03B | -17.12% |
| 2022 | $4.86B | -13.66% |
| 2021 | $5.63B | 49.14% |
| 2020 | $3.78B | 12.15% |
| 2019 | $3.37B | 4.64% |
| 2018 | $3.22B | 5.20% |
| 2017 | $3.06B | 7.98% |
| 2016 | $2.83B | 4.72% |
| 2015 | $2.71B | 6.89% |
| 2014 | $2.53B | 1.54% |
| 2013 | $2.49B | 24.45% |
| 2012 | $2.00B | 11.92% |
| 2011 | $1.79B | 6.54% |
| 2010 | $1.68B | 2.59% |
| 2009 | $1.64B | -2.23% |
| 2008 | $1.67B | 126.78% |
| 2007 | $738.37M | 59.59% |
| 2006 | $462.68M | 60.83% |
| 2005 | $287.68M | 25.79% |
| 2004 | $228.71M | 12.09% |
| 2003 | $204.04M | 7.28% |
| 2002 | $190.19M | 6.56% |
| 2001 | $178.49M | 90.40% |
| 2000 | $93.75M | 0.00% |
Ricavi di aziende simili o concorrenti
| Azienda | Ricavi | Differenza nei ricavi | Il paese |
|---|---|---|---|
| $11.03B | 167.41% |
US
|
|
| $34.74B | 741.81% |
FR
|
|
| - | - |
JP
|
|
| $20.84B | 405.02% |
US
|
|
| - | - |
CH
|
